Bristol Myers Squibb and Hengrui Pharma entered a broad drug research collaboration covering 13 early development programs across oncology, hematology, and immunology. BMS will pay $600 million upfront, and the deal could be worth up to $15.2 billion depending on development, regulatory, and commercial milestones. The agreement combines Hengrui’s R&D capabilities with BMS’s global development and regulatory presence, with Hengrui retaining rights across mainland China, Hong Kong, and Macau while BMS holds rights for the rest of the world. The companies said the portfolio includes assets from both firms plus joint discovery and development programs. For Western biopharma, the pact reinforces how companies are augmenting pipeline risk by partnering with China-based innovation engines—particularly for early-stage programs before later clinical de-risking.